Challenges and Strategies for Achieving Tissue-Specific RNA Delivery in Mouse Models
Achieving tissue-specific RNA delivery in mouse models remains a major challenge in the field of in vivo transfection. Efficient targeting is essential for maximizing therapeutic efficacy while minimizing off-target effects and systemic toxicity.
Biological barriers complicate targeted delivery. Systemic administration exposes RNA therapeutics to degradation by serum nucleases, rapid renal clearance, and sequestration by the mononuclear phagocyte system, especially in the liver and spleen. Additionally, cellular uptake mechanisms and endosomal entrapment limit cytoplasmic access of RNA molecules.
To overcome these challenges, researchers employ ligand-mediated targeting strategies. Conjugation of siRNA or mRNA molecules to ligands such as N-acetylgalactosamine (GalNAc) directs selective uptake by hepatocytes via the asialoglycoprotein receptor. For targeting other tissues, antibodies, aptamers, or peptides recognizing cell surface markers enable receptor-mediated endocytosis.
Nanoparticle formulations further enhance targeting by encapsulating RNA cargo within lipid nanoparticles, polymeric micelles, or liposomes. Surface modifications such as polyethylene glycol (PEG) and tissue-specific ligands improve circulation time and selective binding.
Endosomal escape is critical; delivery systems incorporating ionizable lipids or pH-responsive polymers facilitate release of RNA into the cytoplasm.
Altogen Biosystems develops targeted in vivo transfection reagents and kits optimized for organ-specific delivery in mouse models. Their technologies support selective RNA delivery to liver, lung, brain, pancreas, and kidneys.
Refining tissue-specific RNA delivery methods accelerates preclinical development of RNA therapeutics, enabling precise gene modulation and reducing adverse effects in vivo.